Features (web)

Analysis

Friedreich’s ataxia: major trial readouts and regulatory events to watch in 2023

The FDA could approve the first treatment for Friedreich’s ataxia, and at least three other major trials have readouts expected by year end.

William Newton

Features

Boon and bane: dodging participant burden in decentralised clinical trials

Features

Running low on comparators: navigating drug shortages in oncology clinical trials

Features

ACT EU state of play: EMA’s headway to transform clinical trials

Features

Blockchain in clinical trial supply chains: more hype than heft?

Features

DCT Adoption Tracker: exploring trial decentralisation archetypes by therapy area

Features

CRO consolidation: is the clinical trials industry reaching a tipping point?

Features

Systemic lupus erythematosus: major drug trials to watch in 2022 and 2023

Features

Trial termination analysis unveils a silver lining for patient recruitment

Urtė Fultinavičiūtė

Features

Sustainable supply chains: clinical trials in a new era of limited resources

William Newton

Features

Sex and science: underrepresentation of women in early-stage clinical trials

Urtė Fultinavičiūtė

Features

Can federated learning unlock AI in clinical trials without breaching privacy?

William Newton

Features

The future of medicine in space: drug development, manufacturing, and beyond

William Newton

Features

Sites on wheels: bringing the clinical trial to the patient’s doorstep

Urtė Fultinavičiūtė

Features

External control arms: when can historical data substitute for placebos?

William Newton

Features

Is pharma neglecting the unmet need of substance use disorder therapies?

Urtė Fultinavičiūtė

Features

Alzheimer’s disease: major drug trial results to watch in 2022 and beyond

William Newton

Features

Robotic Process Automation: recruiting bots to accelerate clinical trials

Urtė Fultinavičiūtė

Features

Getting real: who is leading the real-world data charge with clinical trials?

William Newton

Features

DCT Adoption Tracker reveals top therapy areas using a decentralisation approach

Irena Maragkou

Features

Decentralised regulation: What do FDA remote assessments mean for sponsors?

William Newton

News

Multiple monkeypox vaccine and antiviral trials are launching across the world

Urtė Fultinavičiūtė

Ukraine Crisis

As Russia’s clinical trials sector falls, Ukraine rebuilds

Reynald Castañeda

Features

Foreign direct investment in clinical trials revs up after pandemic hit the breaks

Sofia Karadima

Features

Mapping Endpoints in Psoriasis: beyond the mirage of complete skin clearance

William Newton

Features

Can AI remedy the growing pains of digital biomarker development?

Urtė Fultinavičiūtė

Features

Back to the future: the evolution of clinical conference topics in the past decade

Reynald Castañeda

Features

Plaque psoriasis and psoriatic arthritis: trials to watch in 2022

William Newton

Features

Rough diamonds: hiring Gen Z to become future clinical trial experts

Urtė Fultinavičiūtė

Features

Internet of Things: a tsunami of clinical trial data

Reynald Castañeda

Features

Hepatitis B: can GSK’s bepirovirsen deliver functional cure?

Urtė Fultinavičiūtė

Features

Phase 0 clinical trials: what you need to know

William Newton

Features

Glioblastoma: are Phase 0 trials a window of opportunity in drug development?

William Newton

Features

Beyond biopsy: how noninvasive NASH tests can move the needle

Reynald Castañeda

Features

No time to delay: sponsors need to act fast ahead of CTIS deadline

Urtė Fultinavičiūtė

Features

Decentralised paediatric clinical trials trending up but study execution critical

Urtė Fultinavičiūtė

Features

IRT in clinical trials: what to add to your shopping list

Reynald Castañeda

Features

Rule over your eTMF: how to optimise the electronic master file

Urtė Fultinavičiūtė